A Study of ABT-751 in Patients With Renal Cell Cancer

A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00073112

Enrollment

Registered

2003-11-18

Start date

2003-08-31

Completion date

2006-09-30

Last updated

2007-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Cancer

Brief summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Interventions

DRUGABT-751

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Renal Cell Carcinoma. * Recurrent tumor. * At least 6 weeks post-nephrectomy. * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney, and liver function.

Exclusion criteria

* Pregnant or breast feeding. * Anti-tumor therapy within 4 weeks of the start of ABT-751 administration. * CNS metastasis.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate in subjects with RCC	1 year

Secondary

Measure	Time frame
Time to Tumor Progression (TTP)	1 year
Survival	2 years
Toxicities associated with treatment administration	1 year

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026